• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Delcath expands Phase II trial

Delcath expands Phase II trial

December 19, 2014 By Val Kennedy

Delcath expands Phase II trial

Delcath Systems (NSDQ:DCTH) said it added 2 German research centers to a global Phase II trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer.

The 2 facilities, Hannover Medical School Hospital and Jena University Hospital, are open for enrollment in the study. They join Goethe University Hospital in Frankfurt and Moffitt Cancer Center in Tampa, Fla., according to a press release.

The Phase II program is expected to include up to 7 research centers and approximately 30 patients, New York-based Delcath said.

The Chemosat system is designed to isolate the liver from the rest of the circulatory system and then saturate it with the chemotherapy drug melphalan chloride. The system is designed to then remove the drug from the patient’s blood before restoring the connection between the liver and the bloodstream.

Delcath has had a rough ride in the U.S. since May 2013, when a FDA advisory panel declined to recommend approval, citing safety concerns. The FDA later said Delcath would need to conduct additional testing to proceed with the application.

Chemosat is approved in Europe as a delivery system for the drug, but in the U.S. regulators have classified it as a combination drug/device product.

Delcath’s shares have trended steadily downward since the FDA events, sliding from a 2-year high of $31.36 in March 2013 to a 2-year low of $1.09 earlier this month. A 16-to-1 reverse stock split, conducted in April 2014, also pushed down share prices.

In September, Delcath named Jennifer Simpson as interim CEO as part of a broader managerial restructuring.

Delcath shares closed up 5.9% yesterday at $1.43 apiece.

Filed Under: News Well, Oncology Tagged With: Clinical Trials, Delcath Systems Inc.

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy